Please login to the form below

Not currently logged in
Email:
Password:

Receptos

This page shows the latest Receptos news and features for those working in and with pharma, biotech and healthcare.

Alector kicks off next wave of biotech IPOs

Alector kicks off next wave of biotech IPOs

The company is led by Faheem Hasnain and Sheila Gujrathi, two former execs from Receptos - the company bought out by Celgene four years ago for $7.2bn.

Latest news

  • FDA turns down Celgene’s filing for multiple sclerosis drug FDA turns down Celgene’s filing for multiple sclerosis drug

    Ozanimod was acquired by Celgene as part of its $7.2bn takeover of Receptos in 2015, part of a drive to expand its business beyond cancer, a view reiterated by Celgene

  • Celgene spends $7.2bn on Receptos purchase Celgene spends $7.2bn on Receptos purchase

    Celgene will spend $7.2bn to acquire immune and inflammatory specialist Receptos as it looks to broaden its portfolio outside of oncology. ... Bob Hugin, chairman and chief executive of Celgene, said: “The Receptos acquisition provides a

  • Receptos rejected AZ takeover bid, say sources Receptos rejected AZ takeover bid, say sources

    US biopharma Receptos is the latest company to be the subject of M&A speculation, with reports that it has palmed off a $200-per-share takeover offer from AstraZeneca (AZ). ... Receptos' main asset is oxanimod (RPC1063), a sphingosine 1-phosphate 1

  • MS market set to grow 4% annually

    When it comes to branded medicines, Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063 are the projected

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals in July 2015 Pharma deals in July 2015

    Celgene's acquisition of Receptos for $7.2bn is, according to Reuters, rumoured to have been too high a price for AstraZeneca (AZ), Gilead and Teva. ... Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of

  • Pharma deals during March 2013 Pharma deals during March 2013

    Receptos will conduct a phase II proof-of-concept study in Eosinophilic Esophagitis, an orphan indication in the US. ... Receptos will also be eligible for double digit royalties on net sales outside of the US.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics